Related Experiment Video

Updated: May 8, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma

Chao-Ming Lai1, Sandra Horowitz

  • 1The University of Texas, MD Anderson Cancer Center, Department of Lymphoma/Myeloma, 1515 Holcombe Blvd, Houston, TX 77030, USA. clai@mdanderson.org

Expert Review of Hematology
|September 3, 2013
PubMed

Insights

Brentuximab vedotin (Adcetris®) effectively treats relapsed refractory systemic anaplastic large-cell lymphoma, offering durable remissions. Ongoing trials explore its combination with chemotherapy for improved survival outcomes.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • CD30 antigen identification in 1985 paved the way for targeted therapies.
  • Brentuximab vedotin (Adcetris®) is an approved antibody-drug conjugate for relapsed refractory systemic anaplastic large-cell lymphoma (SR-ALCL).

Purpose of the Study:

  • To review the efficacy and safety of brentuximab vedotin in SR-ALCL.
  • To discuss ongoing research evaluating brentuximab vedotin in combination therapies.

Main Methods:

  • Literature review of clinical trials and post-marketing data.
  • Analysis of response rates, remission durability, and adverse events associated with brentuximab vedotin.

Main Results:

  • Brentuximab vedotin demonstrates high response rates and durable remissions in SR-ALCL.
  • Common side effects include peripheral neuropathy, fatigue, and nausea; serious events like Grade 3-4 neutropenia and PML are rare but significant.

Conclusions:

  • Brentuximab vedotin is an effective treatment option for SR-ALCL.
  • Combination strategies with chemotherapy are under investigation to enhance complete remission and survival rates.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...